The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

Recruiting now

Conditions studied: Breast Cancer

In brief

To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.

Key facts

Study ID

NCT05263570

Run by

Shengjing Hospital

People needed

200

Starts

2022-08-01

Expected to finish

2026-12-31

Last updated by the study team

2022-09-13

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years or older
• HR+/HER2- breast cancer diagnosis based on local standards
• Women having stage II-III breast cancer diagnosed based on AJCC cancer staging system (8th edition) who will be admitted because of breast cancer for the first time
• Standard Therapy, determined at the discretion of the investigator, including （TCbHP/THP/EC-THP/AC-THP）
• Complete medical history was available
• Karnofsky Performance Status (KPS) Scale score ≥ 70

You may not qualify if…

• Women who have received any form of anti-tumor treatment - (chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy)
• Pregnant or breast-feeding women
• Those who have bilateral breast cancer, inflammatory breast cancer or occult breast cancer
• Those who have stage IV breast cancer

Where it is running

• Shengjing Hospital of China Medical University — Shenyang, Liaoning, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.